Peri Katya, Khalaf Roy, Baum Alona, Barzilai Aviv, Netchiporouk Elena, Fein Michael Nathan, Ben-Shoshan Moshe
Faculty of Medicine, McGill University, Montreal, Québec, Canada.
Gray Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel.
Int Arch Allergy Immunol. 2025 Jul 24:1-6. doi: 10.1159/000547551.
Chronic spontaneous urticaria (CSU) is increasingly recognized as a significant health issue with significant impacts on quality of life in adult populations. Data are sparse regarding differences in clinical characteristics and management of CU in different countries. We aimed to compare adult CU populations in Canada and Israel to identify demographic, clinical, and management differences.
From 2013 to 2024, Canadian adults with CU were prospectively enrolled at allergy clinics, with clinical data including comorbidities, disease severity (UAS7), control (UCT), and treatment collected. Omalizumab was reserved for refractory cases per guidelines. Israeli adults were recruited from 2009 to 2022 at a dermatology clinic, excluding those with inducible CU or unclear diagnoses. Descriptive statistics and multivariable logistic regression were used to compare demographics and treatment patterns across cohorts using R software.
From 2013 to 2024, 71 adults at the Montreal General Hospital (MGH) and adjutant clinic were diagnosed with spontaneous urticaria, with a median age of 45.8 years (35.2-59.3) and 22.5% male. Between 2009 and 2022, 151 adults at Sheba Hospital were diagnosed with CSU, with a median age of 48.5 years (32.3-60.0) and 32% male. The male prevalence was significantly higher in Israeli CU patients (p < 0.01). Israeli adults had lower reports of comorbidities, including atopic dermatitis (5.3% vs. 19.7%, p < 0.01) and asthma (7.9% vs. 25.4%, p = 0.04). Antihistamine use was higher in Israel (99.3% vs. 85.9%, p < 0.01), along with glucocorticoids (72.8% vs. 14.1%, p < 0.01).
Differences in the demographics, comorbidities, and treatment of CSU may be related to differences between populations and management practices in different countries.
慢性自发性荨麻疹（CSU）日益被视为一个重大的健康问题，对成年人群的生活质量有重大影响。关于不同国家慢性荨麻疹临床特征和管理差异的数据稀少。我们旨在比较加拿大和以色列的成年慢性荨麻疹患者群体，以确定人口统计学、临床和管理方面的差异。
2013年至2024年，加拿大成年慢性荨麻疹患者在过敏诊所进行前瞻性登记，收集包括合并症、疾病严重程度（UAS7）、控制情况（UCT）和治疗情况在内的临床数据。根据指南，奥马珠单抗仅用于难治性病例。2009年至2022年，以色列成年患者在一家皮肤科诊所招募，排除了诱导性慢性荨麻疹或诊断不明确的患者。使用R软件，通过描述性统计和多变量逻辑回归比较各队列的人口统计学和治疗模式。
2013年至2024年，蒙特利尔综合医院（MGH）及附属诊所的71名成年患者被诊断为自发性荨麻疹，中位年龄为45.8岁（35.2 - 59.3岁），男性占22.5%。2009年至2022年，舍巴医院的151名成年患者被诊断为慢性自发性荨麻疹，中位年龄为48.5岁（32.3 - 60.0岁），男性占32%。以色列慢性荨麻疹患者的男性患病率显著更高（p < 0.01）。以色列成年患者合并症报告较少，包括特应性皮炎（5.3%对19.7%，p < 0.01）和哮喘（7.9%对25.4%，p = 0.04）。以色列抗组胺药的使用率更高（99.3%对85.9%，p < 0.01），糖皮质激素的使用率也更高（72.8%对14.1%，p < 0.01）。
慢性自发性荨麻疹在人口统计学、合并症和治疗方面的差异可能与不同国家人群和管理实践的差异有关。
